Coronary atherosclerotic heart disease
Conditions
Interventions
Experimental group:Nourishing Heart Tablets
Control group:placebo
Sponsors
The First Affiliated Hospital of Henan University of CM
Eligibility
Sex/Gender
All
Age
35 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Refer to the Western medical diagnostic criteria for chronic coronary syndrome in the 2024 Chinese Guidelines for the Diagnosis and Management of Patients with Chronic Coronary Syndrome of which (1) is a necessary condition and meets any of the following items (2-4): (1) There are typical clinical symptoms of stable angina pectoris (on the basis of coronary fixed stenosis myocardial acute and transient ischemic-hypoxia syndrome caused by the increase of myocardial load usually transient chest discomfort characterized by transient retrosternal squeezing pain or suffocation which can be induced by exercise mood swings or other stress); (2) Have received percutaneous coronary intervention and CABG therapy; (3) The results of coronary angiography or coronary CT angiography showed that at least one coronary artery was stenosis and the lumen was =50%; (4) Have a clear history of myocardial infarction in the past; 2. Have typical angina pectoris symptoms or equivalent symptoms angina CCS grade I to III; 3. History of previous revascularization (except CABG) coronary angiography or CTA confirmed that at least one coronary artery with a diameter of =1.5mm still has =50% stenosis in the past 1 year; 4. 35 years old= age = 80 years old gender is not limited; 5. At least one anti-angina oral drug (ß receptor blockers nitrates calcium channel blockers potassium channel openers) is currently in use or considered by the doctor to be appropriate; 6. Sign a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those who are suspicious or clearly allergic to any of the ingredients of Yangxinshi tablets; 2. Patients with acute myocardial infarction stroke acute heart failure malignant arrhythmia and moderate or above bleeding defined by GTO within 3 months before enrollment; 3. Patients with well-diagnosed hypertrophic obstructive cardiomyopathy heart failure with NYHA grade IV. or EF value of =40% myocarditis severe valvular disease coronary microcirculation disorder coronary in-stent restenosis requiring intervention moderate or above COPD and moderate or above anemia (HB <90/L) etc.; 4. Patients with severe multivessel lesions indicated for CABG or revascularization plan before randomization before enrollment; 5. Patients with cardiogenic shock malignant arrhythmia and cardiopulmonary resuscitation due to coronary heart disease in the past; 6. Severe abnormal liver function: ALT or AST is more than 3 times higher than the normal range or patients with grade B-C liver cirrhosis; 7. Severe renal function abnormalities: eGFR<30mL/min·1.73m2 or dialysis patients; 8. Pregnant or lactating females; 9. Those who have participated in other clinical studies in the past 3 months; 10. Combined with malignant tumors and other terminal diseases life expectancy is less than 1 year; 11. Patients judged by the investigator to be unsuitable to participate in this study (such as mental disorders limb movement disorders etc.); 12. Patients with absolute and relative contraindications to cardiopulmonary exercise test.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiopulmonary exercise peak metabolic equivalent; | — |
Secondary
| Measure | Time frame |
|---|---|
| Seattle Angina Scale;Hospital Anxiety and Depression Mood Scale;Cardiopulmonary exercise testing;Health Survey Short Form;Renal deficiency and blood stasis pattern score;The incidence rate of major adverse cardiovascular and cerebrovascular events;Proportion of angina pectoris CCS grading improvement;Mini-Cognitive State Assessment Scale; | — |
Countries
China
Contacts
Public ContactWang Yongxia
The First Affiliated Hospital of Henan University of CM
Outcome results
None listed